Hao Zeng Email & Phone Number

Lawrence Township, Nj, Us

* Project Team Leader for small molecule drug discovery programs, coordinating and overseeing cross-functional activities to advance lead optimization assets* Biology Lead for a FIC oncology drug discovery program, supervising a group of scientists for SAR-driving activities, MoA studies, cellular pharmacology characterizations, etc. and successfully delivering a Development Candidate for FIH * Mentor a group of Principal Scientists and contractors to facilitate their contributions to project/team objectives and support their career growth* Foster external partnerships, eg. academic collaborations and CROs, to advance internal portfolio programs* Spearhead various working groups to enable cross-sites/departments communications and collaborations* Partner with cross-site groups and colleagues to nominate and evaluate novel targets to sustain portfolio* Recognized ability to effectively multitask and prioritize across multiple portfolio assets and strategize as appropriate

* Project Team Leader of both FIC and BIC drug discovery projects* Established an integrated drug discovery platform for targeting lineage TFs in breast cancer* Mentored a group of 1 PhD and 2 non-PhD scientists to facilitate their contributions to projects and support their development* Worked with internal teams and Eisai OBG and IPT to assemble preclinical data package to support clinical development strategy and BD discussions* Demonstrated expertise on target ID/validation, assay/model development, HTS, and utilizing biology/DMPK/PD/efficacy data to drive small molecule lead optimization and MoA understanding* Provided strategic directions, scientific perspectives, experimental guidance and go/no-go decisions to various pipeline projects as a scientific core team member* Served as a core member of the “Target Discovery Initiative” to identify the best targets to expand portfolio and design experiments to evaluate target biology* Directly guided experimental strategies and activities at CROs, and managed academic collaborations

* Project Team Leader of the next-generation selective estrogen receptor covalent antagonist (SERCA) drug discovery program, and championed reverse translational research activities for H3B-6545 under clinical investigation* Project Team Leader of WRN exploratory program, and enabled WRN SMI drug discovery effort by successfully influencing SLT decision of moving it into portfolio* Key biology representative and contributor for multiple oncology drug discovery programs, eg. AR PROTAC, DNMT3A activator, PPARr reverse agonist, etc.* Collaborated closely with the medicinal chemistry co-lead and LDO colleagues in the validation and triage of screening hits and SAR exploration around confirmed chemical series* Mentored a group of 1 PhD and 1 non-PhD scientists to facilitate their contributions to various pipeline projects and support their development goals* Managed research activities at CROs and ensured their progress to meet internal timelines

Basel, Baselstadt, Ch

* Designed and executed functional genomic and phenotypic screens to uncover novel regulators of oncogenic signaling pathways, eg. EGFRi sensitivity in NSCLC, Wnt, BMP and YAP signaling in various cancer contexts, resulting in 2 first-author and 1 co-corresponding author publications in PNAS and eLife* Conceived and led the small molecule screen effort to overcome EMT-associated EGFRi resistance mechanism in NSCLC* Initiated and managed cross-departmental collaborations involving chemical biology, oncology, in vivo pharmacology, proteomics, functional genomics and data science from NIBR Cambridge and Basel sites• Elected as a postdoc representative to organize scientific symposium and networking events, strengthening the postdoc community at NIBR

Madison, Wi, Us

Postdoctoral Fellow, McArdle Laboratory for Cancer Research (Dec 2015 - Apr 2016)Graduate Student, Cellular and Molecular Biology Program (Aug 2010 - Dec 2015)Thesis research: epigenetic and transcriptional controls in human breast cancer* Demonstrated Ctr9, a key subunit of human RNA polymerase II associated factor complex, as a central regulator of estrogen signaling and ER-positive breast cancer growth* Designed and executed a collaborative study with proteomics group to profile PRMT4/CARM1-methylated protein substrates in cancer cells, and unraveled a novel mechanism on CARM1-substrate recognition, providing new feasibility to design CARM1-specific inhibitors for cancer therapy* Discovered CARM1-mediated MED12 methylation as a mediator of chemotherapy response in breast cancer using cellular and in vivo models and patient TMA* Established in vitro methylation assays and cellular assays to assess the specificity and potency of novel small molecule inhibitors of CARM1, leading to collaborations with three academic labs* Mentored rotation students on cancer research, project design and data interpretation

Waltham, Ma, Us

* Established and optimized a TR-FRET cellular assay for HTS of small molecule modulators of protein arginine methyltransferase PRMT4/CARM1.* Accomplished a first-author paper describing the optimized TR-FRET HTS assay, highlighted as the ChemBioChem journal cover.

上海, 上海市, Cn

Institute of Developmental Biology and Molecular Medicine* Trained in basic techniques of molecular cloning, cell culture, DNA/RNA isolation, protein expression and purification, western blot, cell imaging, sample preparation for mass spectrometry, among others.* Generated stable cell lines for ectopic protein expression, purification, and functional studies.

Doctor Of Philosophy (Phd), Mcardle Laboratory For Cancer Research

Bachelor'S Degree, Biological And Biomedical Sciences